Status:
COMPLETED
Single and Multiple-Ascending Dose Study of CRN04894 in Healthy Volunteers
Lead Sponsor:
Crinetics Pharmaceuticals Inc.
Conditions:
Healthy Volunteers
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
A Phase 1, first-in-human, double-blind, randomized, placebo-controlled study to evaluate the safety of CRN04894 in healthy volunteers as well as the relationship between exposure and pharmacodynamic ...
Eligibility Criteria
Inclusion
- Females must be either postmenopausal or surgically sterile; or using stable and permitted highly effective method of contraception - use of oral hormonal contraceptives are not allowed during the study
- Male subjects must be surgically sterile or agree to use highly effective form of contraception when sexually active with a female partner of child bearing potential
- ACTH-stimulated serum cortisol high-dose ACTH stimulation test conducted at Screening
Exclusion
- Use of topical, nasal, inhaled, or oral corticosteroids.
- Use of any investigational drug within the past 60 days.
- Have a medically significant illness within 30 days prior to screening.
- Use of prohibited prescribed or nonprescribed medications and/or nonmedications/alternative medicinal products.
- Any condition that in the opinion of the investigator would jeopardize the subject's appropriate participation in this study.
- Unstable psychological disorder ≤1 year prior to Screening.
Key Trial Info
Start Date :
December 18 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 11 2022
Estimated Enrollment :
88 Patients enrolled
Trial Details
Trial ID
NCT06048887
Start Date
December 18 2020
End Date
April 11 2022
Last Update
September 21 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
QPS-Miami Research Associates
Miami, Florida, United States, 33143